ReviewInternational journal of molecular sciences2018
From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer.
Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 5 syntheses or guidelines pooled it, 142 citations in OpenAlex.
- Comparison of overall survival across treatment modalities for oesophageal, gastroesophageal, and gastric cancer: protocol for a systematic review and network meta-analysis.Systematic reviews · 2026Pooled it
- Efficacy and Safety of Conversion Surgery Versus Non-Surgical Treatment for Initially Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Gastric cancer radiation therapy: a bibliometric analysis of the scientific literature.Frontiers in oncology · 2025Pooled it
- Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials.Frontiers in pharmacology · 2022Pooled it
- Efficacy and tolerability of immunotherapy in advanced nasopharyngeal carcinoma with or without chemotherapy: a meta-analysis.Brazilian journal of otorhinolaryngologyPooled it
- Stemness signatures reflect prognostic disturbances in gastric cancer.World journal of gastrointestinal oncology · 2025Article
- Identification of USP39 as a prognostic and predictive biomarker for determining the response to immunotherapy in pancreatic cancer.BMC cancer · 2025Article
- The role of TMEM119 in gastric adenocarcinoma and its specific effects on immunity.The Journal of international medical research · 2025Article
- Meta-analysis of clinical efficacy and safety of immunotherapy combined with chemotherapy in non-small cell lung cancer.Open medicine (Warsaw, Poland) · 2025Article
- Subtype cluster analysis unveiled the correlation between m6A- and cuproptosis-related lncRNAs and the prognosis, immune microenvironment, and treatment sensitivity of esophageal cancer.Frontiers in immunology · 2025Article
- Expression of programmed cell death ligand 1 protein and other biomarkers in patients with gastric cancer and gastroesophageal junction cancer: a retrospective single centre study in Brazil.Frontiers in oncology · 2025Article
- Advancements and challenges in the treatment of esophageal cancer: A comprehensive review.World journal of clinical oncology · 2024Article
- Proximal esophageal adenocarcinoma: A rare case report.International journal of surgery case reports · 2024Article
- Causal relationship between renal function and risk of esophageal cancer: insights from Mendelian randomization.Journal of thoracic disease · 2024Article
- Article
- Prognostic analysis of related factors of adverse reactions to immunotherapy in advanced gastric cancer and establishment of a nomogram model.World journal of gastrointestinal oncology · 2024Article
- Article
- Neoadjuvant chemotherapy plus immunotherapy for locally advanced esophageal cancer.American journal of translational research · 2024Article
- LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma.Future oncology (London, England) · 2024Article
- An immunogenic cell death-related signature predicts prognosis and immunotherapy response in stomach adenocarcinoma.Apoptosis : an international journal on programmed cell death · 2023Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal and gastric cancers represent tumors with poor prognosis. Unfortunately, radiotherapy, chemotherapy, and targeted therapy have made only limited progress in recent years in improving the generally disappointing outcome. Immunotherapy with checkpoint inhibitors is a novel treatment approach that quickly entered clinical practice in malignant melanoma and renal cell cancer, but the role in esophageal and gastric cancer is still poorly defined. The principal prognostic/predictive biomarkers for immunotherapy efficacy currently considered are PD-L1 expression along with defects in mismatch repair genes resulting in microsatellite instability (MSI-H) phenotype. The new molecular classification of gastric cancer also takes these factors into consideration. Available reports regarding PD-1, PD-L1, PD-L2 expression and MSI status in gastric and esophageal cancer are reviewed to summarize the clinical prognostic and predictive role together with potential clinical implications. The most important recently published clinical trials evaluating checkpoint inhibitor efficacy in these tumors are also summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.